Tokyo Gas Company Limited

Kunihiko Shibata

Tadashi Kohno

Isaburo Hosoi

Asuka Ito

Junko Ohshima

Junko Hirayama

Kenji Maeda

Yoshiyuki Sato

Ito Asuka

Nobuo Kato

A preparation for the diagnosis of pancreatic exocrine function by determining the amount in which a substance administered to a subject or a degradation product or metabolite thereof migrates into the blood and/or is excreted out of the body, wherein the substance is carried by a carrier and released from the carrier when exposed to the action of a pancreatic exocrine function-related factor.

Preparation comprising albumin esterified with a labeled substance for diagnosis of pancreatic exocrine function

The present invention provides aC-labeled oligosaccharide or polysaccharide or a salt thereof excluding U&#x2014;C-maltose,C-starch, 1-C-maltotetraose and 1-C-amylose; a derivative of theC-labeled oligosaccharide or polysaccharide or salt thereof; aC-labeled inclusion complex or a salt thereof, which comprises a cyclodextrin or a modified derivative thereof as a host molecule; aC- orC-labeled fluorescein ester compound or a salt thereof; and a diagnostic agents for pancreatic exocrine function comprising these compoundsC- orC-labeled.

Diagnostic agents for pancreatic exocrine function

Method for diagnosis of pancreatic exocrine function

A diagnostic agent for pancreatic exocrine function comprising an amino acid or a peptide containing at least oneC orC atom, or a pharmaceutically acceptable salt thereof other than Bz-Tyr-C-PABA is provided. AC- orC-labeled compound represented by the following formula (II):X&#x2014;R&#x2014;Y&#x2014;Z&#x2003;&#x2003;(II)or a salt thereof,wherein Xis a hydrogen atom or a protecting group,Ris a peptide of 2 to 5 amino acids, an amino acid or a single bond,Yis an amino acid,Zis an amino acid optionally having a protecting group, andat least one of the amino acids in R, Yand Z, or at least one of the protecting groups in Xand Zwhen the protecting groups contain a carbon atom, isC orC-labeled.

Preparations for diagnosis extrapancreatic secretory function

The present invention provides aC-labeled oligosaccharide or polysaccharide or a salt thereof excluding U-C-maltose,C-starch, 1-C-maltotetraose and 1-C-amylose; a derivative of theC-labeled oligosaccharide or polysaccharide or salt thereof; aC-labeled inclusion complex or a salt thereof, which comprises a cyclodextrin or a modified derivative thereof as a host molecule; aC- orC-labeled fluorescein ester compound or a salt thereof; and a diagnostic agents for pancreatic exocrine function comprising these compoundsC- orC-labeled.

The present invention relates to a diagnostic agent for diabetes, which comprises glucose labelled with C at a specific position, or pyruvic acid labelled with C at least one specific position. According to the present invention, there is provided a diagnostic agent for diabetes which can be used safely without side effects to give accurate results immediately with less physical pains on the subject. The present diagnostic agent for diabetes can distinguish between healthy persons and patients with diabetes even under the circumstances where the patients are easily missed, and further it can determine the type of diabetes (insulin-dependent type or insulin-independent type).

Diagnostic method for diabetes using C-13 labeled pyruvic acid

Diagnostic agent for diabetes

The present invention provides a,C-labeled oligosaccharide or polysaccharide or a salt thereof excluding U-,C-maltose,,C-starch, 1-,C-maltotetraose and 1-,C-amylose; a derivative of the,C-labeled oligosaccharide or polysaccharide or salt thereof; a,C-labeled inclusion complex or a salt thereof, which comprises a cyclodextrin or a modified derivative thereof as a host molecule; a,C- or,C-labeled fluorescein ester compound or a salt thereof; and a diagnostic agents for pancreatic exocrine function comprising these compounds,C- or,C-labeled.

The present invention relates to a diagnostic agent for diabetes, which comprises glucose labelled with,C at a specific position, or pyruvic acid labelled with,C at least one specific position. According to the present invention, there is provided a diagnostic agent for diabetes which can be used safely without side effects to give accurate results immediately with less physical pains on the subject. The present diagnostic agent for diabetes can distinguish between healthy persons and patients with diabetes even under the circumstances where the patients are easily missed, and further it can determine the type of diabetes (insulin-dependent type or insulin-independent type).

The present invention relates to a reagent for evaluating a hepatic operation, comprising an aromatic amino acid, methionine, alanine, fructose or galactose labelled with,C at least at one position. According to the present invention, there is provided a reagent for evaluating a hepatic operation, which imposes less physical burden on a subject, can give accurate test results immediately and can be used safely without side effects. The reagent of the invention is useful for measuring the accurate liver excision ratio, liver regeneration/increase ratio or liver weight of a subject after a hepatic operation. With the reagent of the invention, information which is useful for evaluating a hepatic operation and the degree of invasion by the operation and for diagnosis is provided.

Reagent for evaluating a hepatic operation

The present invention relates to a diagnostic agent for liver function, comprising a compound labelled with .sup.13 C at least at one specific position selected from the group consisting of the following (a) to (f):

Diagnostic agent for liver function

The present invention relates to a method of diagnosing diabetes, which comprises administering a diagnostic agent comprising glucose labeled with .sup.13 C at a specific position, or pyruvic acid labeled with .sup.13 C in at least one specific position. According to the present invention, there is provided a method of diagnosing diabetes by administering a diagnostic agent which can be used safely without side effects to give accurate results immediately with less physical pains on the subject. The present method of diagnosing diabetes can distinguish between healthy persons and patients with diabetes even under the circumstances where the patients are easily missed, and further it can determine the type of diabetes (insulin-dependent type or insulin-independent type).

A process for preparing a .sup.13 C-labelled compound which comprises reacting an alcohol .sup.13 C-labelled carbon source compound and a substrate in the presence of an enzyme system consisting of oxidase belonging to EC1 group and capable of converting the alcohol .sup.13 C-labelled carbon source compound to an aldehyde .sup.13 C-labelled carbon source compound, lyase belonging to EC4 group and capable of synthesizing a carbon-carbon bond and at least one of isomerases belonging to EC5 group and capable of isomerizing substrates to obtain a .sup.13 C-labelled compound specifically labelled with .sup.13 C in a specific carbon position.

Growing community of inventors

Chiba, Japan

Kunihiko Shibata